NTRK1 and cancer: Thus, this tyrosine-kinase receptor converges with EGFR and its overactivation mimics that of EGFR, being it a well-documented mechanism for bypassing its blockade and promoting cetuximab resistance across various cancer types, including HNSCC, NSCLC, or CRC [38–40].